Clinical outcomes improve in generalized myasthenia gravis with efgartigimod treatment, suggesting effective management strategies.
Efgartigimod has been shown to rapidly improve clinical symptoms in patients with generalised myasthenia gravis, while also significantly reducing serum IgG levels. When used alongside immunosuppressants, it can help to maintain long-term control of the disease.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: